Trianni’s genetic engineering technology is a platform for developing humanized mice. The acquisition deepens AbCellera’s technology stack with a suite of genetically engineered mice for generating diverse panels of human antibodies with drug-like properties.
“Trianni marks our fourth and largest strategic technology addition to date. With its technology and team, Trianni amplifies our capability to generate human antibodies and provides a strong foundation for developing increasingly powerful transgenic mouse technologies,” said Carl Hansen, Ph.D., CEO of AbCellera.
“Trianni adds a key pillar to our platform, which now includes genetically engineered rodents, microfluidic single-cell screening, repertoire sequencing, AI-powered computation, and bispecific protein engineering. By integrating these technologies, we aim to provide our partners with access to a modern operating system that improves the speed and probability of success of antibody drug development.”
The flagship Trianni Mouse® was designed to maximize immune responses, increase antibody diversity, and preserve natural maturation of fully human antibodies in rodents. The Trianni Mouse is also a core platform that supports the rapid development of new mouse strains tailored to address the most challenging antibody discovery programs.